Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

T-Cell Lymphoma Clinical Trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (26) clinical trials

Kappa-CD28 T Lymphocytes Chronic Lymphocytic Leukemia B-cell Lymphoma or Multiple Myeloma CHARKALL

To prepare the lymphoma, MM or CLL specific T cells investigators will take 240 ml (up to 16 tablespoonfuls)of blood from the patient. This would be drawn as 2 (two) separate blood collections of 120 ml (up to 8 tablespoonfuls) of blood. To get the kappa antibody (with CD28) to ...


A clinical trial sponsored by Eisai Inc. for a research study for the treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma

This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL). The study will consist of an initial lead-in phase (in which a dose of E7777 will be selected), followed by the Main Study. Participants will move through three phases while on ...


Ruxolitinib for Adult T-Cell Leukemia

Background Adult T-cell leukemia is a lymphoproliferative disorder characterized by the presence of CD4/CD25 expressing T cells (IL-2R alpha expressing) in the peripheral blood, in lymphoid and other tissues. In smoldering and chronic ATL the HTLV-1 encoded protein, Tax constitutively activates interleukin-2 (IL-2), IL-9 and IL-15 autocrine/paracrine systems that in ...


A clinical trial seeking patients for a research study for the treatment of Recurrent Mycosis Fungoides/Sezary Syndrome, ESSENTIAL THROMBOCYTHEMIA, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Lymphoblastic Lymphoma, Refractory Cytopenia With Multilineage Dysplasia, anaplastic large cell lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Anemia with Excess of Blasts, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Waldenstrom's Macroglobulinemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Childhood Myelodysplastic Syndromes, Recurrent Childhood Acute Myeloid Leukemia, chronic phase chronic myelogenous leukemia, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Relapsing Chronic Myelogenous Leukemia, Chronic myelomonocytic leukemia, Recurrent Adult T-cell Leukemia/Lymphoma, de Novo Myelodysplastic Syndromes, Childhood Chronic Myelogenous Leukemia, Myelosclerosis with myeloid metaplasia, Testicular Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Intraocular Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Secondary Acute Myeloid Leukemia, Hepatosplenic T-cell Lymphoma, Polycythemia Vera, Blast Crisis, T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, Angioimmunoblastic Lymphadenopathy, Refractory Hairy Cell Leukemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Multiple Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Noncutaneous Extranodal Lymphoma, Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Adult Acute Myeloid Leukemia With Del(5q), Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Post-transplant Lymphoproliferative Disorder, Small Intestine Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent/Refractory Childhood Hodgkin Lymphoma, Childhood Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Nodal Marginal Zone B-cell Lymphoma, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...


A clinical trial seeking patients for a research study of Romidepsin

PRIMARY OBJECTIVES: I. To establish the safety and tolerability of romidepsin given on days 1, 8, and 15 of a 28 day cycle to patients with varying degrees of liver dysfunction (mild, moderate and severe). II. To establish the maximum tolerated dose (MTD) and appropriate dosing recommendations for romidepsin in ...


T Cell Repertoire Analysis of Immune Mediated Skin Diseases

The aim of the study is to characterized the T cell repertoire of individuals with immune mediated skin disease (e.g. psoriasis and mycosis fungoides). Peripheral blood with be collected from volunteers with psoriasis, mycosis fungoides and age matched controls. Fifteen tablespoons of blood will be collected prior to the initiation ...

Phase N/A

Patients are needed to participate in a clinical research study evaluating Duvelisib

The study has 2 phases, a Dose Optimization Phase and an Expansion Phase. In the Dose Optimization Phase, patients will be randomly assigned to 1 of 2 study cohorts, as follows: Cohort 1: Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis ...


A Phase 3 clinical study for patients using Mycophenolate mofetil, methotrexate, Methotrexate (low dose), tacrolimus

Study Design This is a prospective randomized trial to determine the effectiveness of different doses of GVHD prophylaxis on mucositis, engraftment and aGVHD. Study consists of two study groups of 50 subjects each. Group A will receive Tac and MTX (15 mg/m2 day +1, 10 mg/m2 day +3, +6, +11). ...


Patients are needed to participate in a clinical research study evaluating Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Busulfan, Pre-HCT Mesna on Days -2 and -1, Post-HCT Mesna, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Mycophenolate mofetil, Sirolimus, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Fludarabine, G-CSF, Pre-HCT Mesna on Days -5 and -4, Pre-HCT Mesna on Days -6 and -5

This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host disease (GVHD) prophylaxis in patients with hematologic malignancies.


A Phase 2 clinical study for patients using Sapanisertib

PRIMARY OBJECTIVES: I. To determine the complete hematologic response (CR)/complete response incomplete (CRi) rate when sapanisertib (MLN0128 [TAK-228]) is administered to adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). SECONDARY OBJECTIVES: I. To determine the overall response rate (CR, CRi/partial response (PR)/morphologic leukemia free state [MLFS]). II. To determine the ...